
Microbot Medical MBOT
$ 1.85
0.0%
Quarterly report 2026-Q1
added 05-13-2026
Microbot Medical Gross Profit 2011-2026 | MBOT
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Microbot Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 117 K | 1.01 M | 887 K | 1.1 M | 1.01 M | 1.26 M | 731 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 M | 117 K | 874 K |
Quarterly Gross Profit Microbot Medical
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 212 K | 164 K | 252 K | - | 239 K | 204 K | 217 K | - | 192 K | 185 K | 572 K | - | 163 K | 182 K | 167 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 572 K | 2 K | 212 K |
Gross Profit of other stocks in the Medical instruments industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
2.68 B | $ 59.61 | -1.28 % | $ 11.9 B | ||
|
Atrion Corporation
ATRI
|
62.4 K | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
248 M | - | - | $ 1.75 B | ||
|
iRhythm Technologies
IRTC
|
527 M | $ 114.0 | -0.14 % | $ 3.65 B | ||
|
ICU Medical
ICUI
|
822 M | $ 118.72 | -3.47 % | $ 2.93 B | ||
|
Repro Med Systems
KRMD
|
25.6 M | $ 3.9 | -2.01 % | $ 180 M | ||
|
Akers Biosciences, Inc.
AKER
|
479 K | - | -9.52 % | $ 20.6 M | ||
|
Intuitive Surgical
ISRG
|
6.64 B | $ 421.12 | -1.62 % | $ 150 B | ||
|
LeMaitre Vascular
LMAT
|
179 M | $ 97.31 | -2.2 % | $ 2.2 B | ||
|
Alcon
ALC
|
5.74 B | $ 63.64 | -0.56 % | $ 40.4 B | ||
|
Masimo Corporation
MASI
|
1 B | $ 178.47 | 0.07 % | $ 9.51 B | ||
|
Antares Pharma, Inc.
ATRS
|
86.5 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
436 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
1.68 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
1.48 B | - | -0.05 % | $ 10.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
6.84 M | - | - | $ 28.6 M | ||
|
Envista Holdings Corporation
NVST
|
1.49 B | $ 23.22 | -2.68 % | $ 3.9 B | ||
|
Varian Medical Systems, Inc.
VAR
|
1.38 B | - | -0.02 % | $ 16.3 B | ||
|
electroCore
ECOR
|
27.8 M | $ 6.27 | -2.49 % | $ 53.2 K | ||
|
Haemonetics Corporation
HAE
|
749 M | $ 56.29 | -1.4 % | $ 2.83 B | ||
|
Isoray
ISR
|
1.43 M | - | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
239 M | $ 144.01 | 1.31 % | $ 6.97 B | ||
|
STAAR Surgical Company
STAA
|
182 M | $ 32.07 | 0.19 % | $ 1.59 B | ||
|
STERIS plc
STE
|
2.4 B | $ 212.11 | -1.79 % | $ 20.9 B | ||
|
Teleflex Incorporated
TFX
|
307 M | $ 129.71 | -0.44 % | $ 5.79 B | ||
|
InfuSystem Holdings
INFU
|
80.3 M | $ 8.77 | 1.86 % | $ 181 M | ||
|
Milestone Scientific
MLSS
|
6.41 M | $ 0.33 | -2.62 % | $ 27.1 M | ||
|
Merit Medical Systems
MMSI
|
738 M | $ 61.36 | -1.92 % | $ 3.63 B | ||
|
Utah Medical Products
UTMD
|
5.26 M | $ 63.34 | -0.57 % | $ 205 M | ||
|
West Pharmaceutical Services
WST
|
1.1 B | $ 302.89 | 0.9 % | $ 21.9 B | ||
|
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 10.08 | -3.17 % | $ 2.01 B | ||
|
Retractable Technologies
RVP
|
47 K | $ 0.64 | -7.25 % | $ 19.2 M | ||
|
Pro-Dex
PDEX
|
19.5 M | $ 59.27 | 1.06 % | $ 195 M | ||
|
Predictive Oncology
POAI
|
1.02 M | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
62.1 M | $ 20.76 | -1.42 % | $ 991 M | ||
|
Stereotaxis
STXS
|
17.1 M | $ 1.85 | -4.64 % | $ 168 M | ||
|
Baxter International
BAX
|
3.38 B | $ 17.3 | -2.7 % | $ 8.87 B | ||
|
ResMed
RMD
|
2.02 B | $ 201.88 | -0.33 % | $ 29.5 B | ||
|
AtriCure
ATRC
|
401 M | $ 28.12 | -0.11 % | $ 1.34 B | ||
|
Harvard Bioscience
HBIO
|
49.9 M | $ 5.25 | -4.89 % | $ 233 M | ||
|
NeuroMetrix
NURO
|
1.68 M | - | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
158 M | $ 10.77 | -2.36 % | $ 440 M | ||
|
Becton, Dickinson and Company
BDX
|
8.29 B | $ 143.47 | -0.73 % | $ 41.3 B | ||
|
Nephros
NEPH
|
11.6 M | $ 3.13 | -6.29 % | $ 33.2 M | ||
|
OraSure Technologies
OSUR
|
48.2 M | $ 3.0 | 1.69 % | $ 220 M | ||
|
Repligen Corporation
RGEN
|
151 M | $ 102.87 | -0.49 % | $ 5.78 M |